FABP4 and Insulin resistance: Excessive expression or ectopic expression of FABP4 was proven to contribute to the multiple components of metabolic diseases and subsequent adverse outcomes, such as insulin resistance, dyslipidemia, obesity, metabolic syndrome, hypertension, type 2 diabetes, atherosclerosis and cardiovascular diseases [20–23].